|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...8586878889909192939495...156157» |
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: Enbrel-JIA: Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance] (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=113, Completed, Sponsor: Pfizer
Phase classification: P4 --> P=N/A
- ||| Clinical: An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT) (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=224, Recruiting, Sponsor: Abbott Diabetes Care
- | Trial completion, Enrollment change: The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device (clinicaltrials.gov) - Sep 5, 2014
P4, N=20, Completed, Sponsor: Insuline Medical Ltd.
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed | N=40 --> 20
- Trial primary completion date: Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial (clinicaltrials.gov) - Sep 4, 2014
P4, N=50, Recruiting, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | N=40 --> 20 Trial primary completion date: Dec 2014 --> Aug 2015
- |||| dimethyl fumarate / Generic mfg., aspirin / Generic mfg.
Enrollment open, P4 data: Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 4, 2014
P4, N=240, Recruiting, Sponsor: Biogen Idec
Trial primary completion date: Dec 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- ||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed: Extension Study of MT-1303 (clinicaltrials.gov) - Sep 4, 2014
P2, N=400, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- |||| Trial completion, Trial primary completion date: BONARTH: Benefit of Orthopedic Navigation in the ARThroplasty of the Hip (clinicaltrials.gov) - Sep 4, 2014
P4, N=89, Completed, Sponsor: Aesculap AG
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2013
- hydroxychloroquine / Generic mfg.
Enrollment change: RA PLUS: Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis (clinicaltrials.gov) - Sep 4, 2014
P3, N=30, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2013 N=23 --> 30
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=18, Completed, Sponsor: University of Calgary
N=23 --> 30 N=130 --> 18
- Clinical: A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=675, Not yet recruiting, Sponsor: Novo Nordisk A/S
- DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Clinical: Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=1000, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Enrollment closed, Trial primary completion date: Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 4, 2014
P2, N=28, Active, not recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
N=130 --> 18 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2014
- Trial completion, Enrollment change: Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp (clinicaltrials.gov) - Sep 4, 2014
P2, N=33, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2014 Recruiting --> Completed | N=22 --> 33
- | BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
Trial completion: A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog (clinicaltrials.gov) - Sep 4, 2014
P1, N=37, Completed, Sponsor: Adocia
Recruiting --> Completed | N=22 --> 33 Recruiting --> Completed
- | BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
Trial completion: A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Sep 4, 2014
P1, N=21, Completed, Sponsor: Adocia
Recruiting --> Completed Recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion: MTX-IR: Methotrexate-Inadequate Response Autoinjector Device Sub Study (clinicaltrials.gov) - Sep 4, 2014
P3, N=120, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Enrolling by invitation --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
Trial termination, Trial primary completion date: STRATA: Natalizumab (Tysabri) Re-Initiation of Dosing (clinicaltrials.gov) - Aug 29, 2014
P3, N=716, Terminated, Sponsor: Biogen Idec
Enrolling by invitation --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Apr 2014
- | MIS416 / Amplia Therap
New P2b trial: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2014
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
- apremilast / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) (clinicaltrials.gov) - Aug 29, 2014
P2, N=34, Completed, Sponsor: Baylor Research Institute
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Apr 2014 Recruiting --> Completed | N=50 --> 34 | Trial primary completion date: Oct 2014 --> May 2014
- Trial primary completion date, HEOR: Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyro (clinicaltrials.gov) - Aug 29, 2014
P3, N=200, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Completed | N=50 --> 34 | Trial primary completion date: Oct 2014 --> May 2014 Trial primary completion date: Dec 2013 --> Nov 2014
- leucovorin calcium / Generic mfg.
Enrollment change: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Aug 29, 2014
P2, N=192, Recruiting, Sponsor: University of Arkansas
Trial primary completion date: Dec 2013 --> Nov 2014 N=144 --> 192
- New P4 trial: COBOL: Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients (clinicaltrials.gov) - Aug 29, 2014
P4, N=21, Not yet recruiting, Sponsor: University Hospital, Toulouse
- ||| Betaseron (IFN-?-1b) / Bayer
Trial completion, Adherence: SEPLUS: Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=80, Completed, Sponsor: Bayer
N=144 --> 192 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Enrollment change, Trial primary completion date, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Aug 28, 2014
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Feb 2015 --> Jul 2016
- NN1953 / Novo Nordisk
Enrollment open: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 28, 2014
P1, N=66, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Feb 2015 --> Jul 2016 Not yet recruiting --> Recruiting
- Diamyd (rhGAD65/alum) / Diamyd Medical
Enrollment closed, Combination therapy: DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen (clinicaltrials.gov) - Aug 28, 2014
P2, N=60, Active, not recruiting, Sponsor: Johnny Ludvigsson
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | bertilimumab (iCo-008) / iCo Therap, AstraZeneca
New P2 trial: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Aug 27, 2014
P2, N=15, Not yet recruiting, Sponsor: Immune Pharmaceuticals
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion, Trial primary completion date: REASSURE2: Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (clinicaltrials.gov) - Aug 27, 2014
P3, N=234, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jan 2020 --> Jul 2014
- || Enrollment change, Trial primary completion date: A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement (clinicaltrials.gov) - Aug 27, 2014
P=N/A, N=100, Recruiting, Sponsor: Medacta International SA
Recruiting --> Completed | Trial primary completion date: Jan 2020 --> Jul 2014 N=50 --> 100 | Trial primary completion date: Jan 2013 --> Jan 2015
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
New P4 trial: ACTHar in the Treatment of Lupus Nephritis (clinicaltrials.gov) - Aug 27, 2014
P4, N=20, Recruiting, Sponsor: Columbia University
- | dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap
Trial completion: Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 27, 2014
P1, N=24, Completed, Sponsor: UCB, Inc.
N=50 --> 100 | Trial primary completion date: Jan 2013 --> Jan 2015 Active, not recruiting --> Completed
- Enrollment open: Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=50, Recruiting, Sponsor: Örebro County Council
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Allerdiab: Diagnosis and Physiopathology of Insulin Allergy (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=70, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Aug 2015
- MEDI-570 / AstraZeneca, Japan Tobacco
Enrollment change: A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 26, 2014
P1, N=44, Terminated, Sponsor: MedImmune LLC
Trial primary completion date: Sep 2014 --> Aug 2015 N=17 --> 44
- fingolimod / Generic mfg.
Clinical: Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=125, Recruiting, Sponsor: University of Southern California
- Trial completion, Enrollment change: Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=83, Completed, Sponsor: Duke University
N=17 --> 44 Recruiting --> Completed | N=60 --> 83
- Trial primary completion date: CTSM: Effects of the Cross-Training in Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 25, 2014
P1/2, N=45, Recruiting, Sponsor: Università degli Studi di Sassari
Recruiting --> Completed | N=60 --> 83 Trial primary completion date: Mar 2014 --> Nov 2014
- Enrollment change: Outpatient Control-to-Range: System and Monitoring Testing (clinicaltrials.gov) - Aug 25, 2014
P=N/A, N=20, Completed, Sponsor: University of Virginia
Trial primary completion date: Mar 2014 --> Nov 2014 N=10 --> 20
- selurampanel (BGG492) / Novartis
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - Aug 22, 2014
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=10 --> 20 N=145 --> 0 | Initiation date: Nov 2012 --> Oct 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2013 --> Mar 2018
- ||||| vatelizumab (GBR 500) / Glenmark
New P2 trial: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 22, 2014
P2, N=168, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- prednisone / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN) (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=176, Completed, Sponsor: Zhi-Hong Liu, M.D.
N=145 --> 0 | Initiation date: Nov 2012 --> Oct 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2013 --> Mar 2018 Recruiting --> Completed | N=50 --> 176 | Trial primary completion date: Jun 2013 --> Oct 2013
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed, Trial primary completion date: RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) - Aug 22, 2014
P3, N=700, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Completed | N=50 --> 176 | Trial primary completion date: Jun 2013 --> Oct 2013 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2014
- fletikumab (NNC109-0012) / Novo Nordisk
Trial primary completion date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Aug 21, 2014
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2014 Trial primary completion date: Feb 2015 --> Nov 2014
- |||||||||| Ixifi (infliximab biosimilar) / Pfizer, Novartis
New P3 trial, Combination therapy: A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02). (clinicaltrials.gov) - Aug 21, 2014
P3, N=614, Not yet recruiting, Sponsor: Pfizer
- Biomarker, Enrollment open: Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=170, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Trial primary completion date: Feb 2015 --> Nov 2014 Not yet recruiting --> Recruiting
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment closed, Trial primary completion date: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Aug 21, 2014
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Nov 2014
- ||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barr (clinicaltrials.gov) - Aug 21, 2014
P3, N=21, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
New P2 trial: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Aug 21, 2014
P2, N=45, Not yet recruiting, Sponsor: ChemoCentryx
- New P2 trial: A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1 (clinicaltrials.gov) - Aug 21, 2014
P2, N=13, Not yet recruiting, Sponsor: Profil Institut f